Source in Chinese: Commercial Times
TFBS Bioscience Inc. announced on 2 October that it has set up a subsidiary in Tokyo, Japan, and moved into regenerative medicine platform in Kashiwanoha Smart City to expand its manufacturing and testing business; in addition, the company has entered into an alliance with Teijin Limited in March this year for cooperation in the Japanese market.
TFBS Bioscience has signed a contract with Mitsui Fudosan Co., Ltd. to formally enter a life science business park in Kashiwa-shi, Chiba Prefecture, Japan. Initially, it will set up a production laboratory and an office to provide viral vectors for research and development, and promote one-stop service from R&D to commercial production of cellular and gene therapies.
The Kashiwanoha Smart City is surrounded by important biomedical research and development units such as the University of Tokyo, Chiba University, and the National Cancer Centre Japan, which allows for the next generation of medical and biotechnological research and applications.
The new facility will allow TFBS Bioscience to quickly enter the emerging regenerative medicine cluster in Kanto area and collaborate with the academic and research institutes, biotech-medical and start-up companies gathered there to develop viral vector manufacturing business.
TFBS Bioscience has been developing the Japanese market. In March this year it signed a collaboration agreement with Teijin and Mediridge. Teijin Limited, Japan Tissue Engineering Co., Ltd. (J-TEC), Mitsui Fudosan Co., Ltd. and the National Cancer Center (NCC) have jointly established a regenerative medicine platform in Kashiwanoha. The goal is to create innovative treatments for unresolved diseases and create a one-stop shop for cell and gene therapy from research and development to commercial production.
According to TFBS Bioscience, its technology of viral vector manufacturing and testing can meet the needs of Japanese enterprises and academic institutions for critical materials from R&D to commercial production, and help Japanese cell and gene therapy development companies and research institutes develop and manufacture from preclinical research to clinical phase I and phase II trials in order to support the development and launch of new drugs.
The viral vector manufacturing market is expected to grow from US$5.5 billion in 2023 to US$12.8 billion in 2028, at a CAGR of 18.2%. More than 2,000 cell and gene therapies are currently in clinical trials worldwide, which will drive the rapid growth of the market.